HLA-DRB1 Antibody [L243]

Flow Cytometry: 0.5-1 ug/million cells in 0.1ml

Immunofluorescence: 0.5-1 ug/ml

Optimal dilution of the HLA-DRB1 antibody should be determined by the researcher.

This mAb reacts with the HLA-DRB1 antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. It binds a conformational epitope on HLA-DR, which depends on the correct folding of the alpha/beta heterodimer. This mAb has been reported to block mixed lymphocyte reactions. The L243 antibody recognizes a different epitope than the LN3 monoclonal antibody, and these antibodies do not cross-block binding to each other's respective epitopes. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kD alpha (heavy) chain and a 28kD beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts.

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

0.2 mg/mL

Unconjugated

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

Activated human peripheral blood mononuclear cells were used as the immunogen for the HLA-DRB1 antibody.

3123

major histocompatibility complex, class II, DR beta 1

HLA-DRB1

Homo sapiens

Liquid

Protein G affinity chromatography

Immunology

P01911

Optimal dilutions for each application to be determined by the researcher